Replying to a new brand owner's manufacturing enquiry without giving regulatory advice

A first-time brand owner writes to a contract plant and asks which licence is needed, whether you can get the product approved and what to print on the carton. Reply on three things only. Say what your plant makes, with forms, batch sizes and the documents you can share. Name, in plain words, what the brand owner must arrange through a regulatory adviser. Then offer a next step on what you control. Answering the regulatory questions yourself feels like good service. It is also the quickest way to own a mistake that was never yours.

Why the helpful answer goes wrong

Sales managers at contract plants hear the same questions so many times that they feel they know the answers. Some do, for the last product they handled. But three questions turn on the product, the state and the authority. Who must hold which registration? Is the product a drug, a supplement or an Ayurvedic item? What may the carton claim? Rules differ by state and body and change, so check with your own adviser or the regulator. An answer that was right for last year's client can be wrong for this one.

And once a plant answers in writing, the brand owner builds on it: registers a company, orders artwork, tells distributors a launch date. If the answer was wrong, the plant is blamed, and fairly.

Three lanes for every question

Sort each question in the enquiry into one of three lanes before anyone types a reply.

The middle column is the whole method. Anything marked "adviser" gets one honest sentence and no opinion.

A reply that stays in your lane

Here is a first reply for an email or a long WhatsApp message. Fill the brackets from your own records; never send it with a bracket left in.

Thank you for writing to us about your new range.

What we make: (forms and lines). Our smallest batch for (form) is (quantity) in (pack).

What we can share: our manufacturing permissions, product list and plant certificates now; batch records and validation documents after a confidentiality agreement.

What you arrange: your brand's registrations and permissions, how your product is classified, and the wording on your label and carton. These depend on the product and the state, and they change, so your regulatory adviser or the authority confirms them. If you have no adviser yet, we can share a few names; we have no arrangement with any of them. (Keep this line only if it is true.)

To quote you, we need: product names and strengths, pack sizes, first order quantity, and where you will sell.

Next step: a call with (name), (designation), on (day). Reply with a time that suits you.

Notice what it does not say. No view on the licence. No suggestion of which claim is "safe enough". No promise of an approval date. The reply is still warm, and it answers every question that is yours.

For example: a pharmacy owner in Nagpur and a plant in Selaqui

Imagine, as an invented example, a pharmacy chain owner in Nagpur who wants an own brand of multivitamin tablets and a calcium syrup. The owner writes to a tablet and liquids plant in Selaqui, near Dehradun. The sales manager, keen on the order, says by WhatsApp that both products need no drug permission and that "boosts immunity" is fine on the carton. The owner prints a large run of cartons, about ₹1.8 lakh of printing. A pharmacist friend reads one and asks who approved the wording. Nobody had. The cartons are scrapped, and the owner stops taking the plant's calls.

Run the same enquiry through the three lanes. Forms, batch sizes and documents go back the same day. The classification and the carton wording go to the owner's adviser, with the plant's documents ready for that adviser. The plant reviews the final artwork only for fit and print. The sales manager's eagerness is the same; it is simply spent on what the plant controls. The cost is a slower start: the adviser takes a few weeks, and the owner may decide to wait for another plant that answers faster.

When to drop the "what you arrange" block

Cut it for an established brand with its own regulatory team. They know, and a paragraph explaining their own job reads as patronising. Keep the rest of the reply. Such a brand will also judge you against other plants on its shortlist, a process the pharmaceutical manufacturing page describes from the brand owner's side.

Drop the whole method if your plant does sell regulatory support as a paid service. Then put that service in its own written scope, done by a qualified person, with its own fee, and not folded into a sales reply as a free answer.

And say no to the enquirer who wants the plant to be the regulatory department: "you handle everything, I will only sell". State what you do and stop there.

Put the lanes into your sales material

A one-page "working with us" sheet saves the same reply being typed every day. It lists your forms and batch sizes, the documents you share and when, what the client arranges, and how artwork approval works between you. Telling brand owners from traders is a separate step; our post on Baddi pharma enquiries covers it.

Sort your last ten replies into the lanes

Open the last ten replies your team sent to new brand owners and mark every sentence yours, the adviser's, or shared. Each sentence in the wrong lane is a line to cut from your standard reply. If you want the reply, the sheet (sales collateral development) and the qualifying questions set up together, tell us what you need.